CHARLES RIVER LABORATORIES (CRL) Fundamental Analysis & Valuation
NYSE:CRL • US1598641074
Current stock price
167.03 USD
-6.86 (-3.95%)
Last:
This CRL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CRL Profitability Analysis
1.1 Basic Checks
- CRL had positive earnings in the past year.
- CRL had a positive operating cash flow in the past year.
- Of the past 5 years CRL 4 years were profitable.
- CRL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -2.02%, CRL perfoms like the industry average, outperforming 59.65% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -4.56%, CRL is in line with its industry, outperforming 59.65% of the companies in the same industry.
- CRL's Return On Invested Capital of 6.60% is fine compared to the rest of the industry. CRL outperforms 77.19% of its industry peers.
- CRL had an Average Return On Invested Capital over the past 3 years of 6.85%. This is below the industry average of 11.38%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.02% | ||
| ROE | -4.56% | ||
| ROIC | 6.6% |
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
1.3 Margins
- CRL has a better Operating Margin (12.51%) than 73.68% of its industry peers.
- In the last couple of years the Operating Margin of CRL has declined.
- With a Gross Margin value of 34.98%, CRL is not doing good in the industry: 63.16% of the companies in the same industry are doing better.
- In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.51% | ||
| PM (TTM) | N/A | ||
| GM | 34.98% |
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
2. CRL Health Analysis
2.1 Basic Checks
- CRL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for CRL has been reduced compared to 1 year ago.
- CRL has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for CRL is higher compared to a year ago.
2.2 Solvency
- CRL has an Altman-Z score of 2.42. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
- CRL's Altman-Z score of 2.42 is fine compared to the rest of the industry. CRL outperforms 61.40% of its industry peers.
- CRL has a debt to FCF ratio of 4.13. This is a neutral value as CRL would need 4.13 years to pay back of all of its debts.
- The Debt to FCF ratio of CRL (4.13) is better than 73.68% of its industry peers.
- CRL has a Debt/Equity ratio of 0.68. This is a neutral value indicating CRL is somewhat dependend on debt financing.
- CRL has a Debt to Equity ratio of 0.68. This is in the lower half of the industry: CRL underperforms 70.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | 4.13 | ||
| Altman-Z | 2.42 |
ROIC/WACC0.63
WACC10.52%
2.3 Liquidity
- A Current Ratio of 1.29 indicates that CRL should not have too much problems paying its short term obligations.
- CRL has a worse Current ratio (1.29) than 82.46% of its industry peers.
- A Quick Ratio of 1.02 indicates that CRL should not have too much problems paying its short term obligations.
- With a Quick ratio value of 1.02, CRL is not doing good in the industry: 82.46% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.02 |
3. CRL Growth Analysis
3.1 Past
- CRL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.39%.
- Measured over the past 5 years, CRL shows a small growth in Earnings Per Share. The EPS has been growing by 4.78% on average per year.
- Looking at the last year, CRL shows a decrease in Revenue. The Revenue has decreased by -0.85% in the last year.
- CRL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.55% yearly.
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
3.2 Future
- CRL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.31% yearly.
- Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 3.54% on average per year.
EPS Next Y8.47%
EPS Next 2Y8.74%
EPS Next 3Y8.89%
EPS Next 5Y9.31%
Revenue Next Year-0.59%
Revenue Next 2Y1.18%
Revenue Next 3Y2.21%
Revenue Next 5Y3.54%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. CRL Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 16.25, CRL is valued correctly.
- 91.23% of the companies in the same industry are more expensive than CRL, based on the Price/Earnings ratio.
- CRL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.17.
- CRL is valuated correctly with a Price/Forward Earnings ratio of 14.98.
- Based on the Price/Forward Earnings ratio, CRL is valued cheaply inside the industry as 89.47% of the companies are valued more expensively.
- CRL is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.05, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.25 | ||
| Fwd PE | 14.98 |
4.2 Price Multiples
- 94.74% of the companies in the same industry are more expensive than CRL, based on the Enterprise Value to EBITDA ratio.
- CRL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CRL is cheaper than 89.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.86 | ||
| EV/EBITDA | 11.58 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CRL does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)1.92
PEG (5Y)3.4
EPS Next 2Y8.74%
EPS Next 3Y8.89%
5. CRL Dividend Analysis
5.1 Amount
- No dividends for CRL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CRL Fundamentals: All Metrics, Ratios and Statistics
NYSE:CRL (4/6/2026, 3:41:54 PM)
167.03
-6.86 (-3.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-18 2026-02-18/bmo
Earnings (Next)05-05 2026-05-05/bmo
Inst Owners110.03%
Inst Owner Change-0.02%
Ins Owners0.94%
Ins Owner Change5.84%
Market Cap8.22B
Revenue(TTM)4.02B
Net Income(TTM)-144.34M
Analysts78.26
Price Target206.34 (23.53%)
Short Float %7.72%
Short Ratio3.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.93%
Min EPS beat(2)0.98%
Max EPS beat(2)2.88%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)0.98%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.14%
EPS beat(12)12
Avg EPS beat(12)7.96%
EPS beat(16)16
Avg EPS beat(16)6.74%
Revenue beat(2)1
Avg Revenue beat(2)0.06%
Min Revenue beat(2)-0.27%
Max Revenue beat(2)0.38%
Revenue beat(4)3
Avg Revenue beat(4)1.83%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)3.74%
Revenue beat(8)6
Avg Revenue beat(8)1.34%
Revenue beat(12)9
Avg Revenue beat(12)1.37%
Revenue beat(16)11
Avg Revenue beat(16)1.18%
PT rev (1m)0.03%
PT rev (3m)2.47%
EPS NQ rev (1m)-0.26%
EPS NQ rev (3m)-25.21%
EPS NY rev (1m)0%
EPS NY rev (3m)1.64%
Revenue NQ rev (1m)-0.14%
Revenue NQ rev (3m)-1.82%
Revenue NY rev (1m)-1.88%
Revenue NY rev (3m)-2.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.25 | ||
| Fwd PE | 14.98 | ||
| P/S | 2.05 | ||
| P/FCF | 15.86 | ||
| P/OCF | 11.15 | ||
| P/B | 2.6 | ||
| P/tB | 136.18 | ||
| EV/EBITDA | 11.58 |
EPS(TTM)10.28
EY6.15%
EPS(NY)11.15
Fwd EY6.68%
FCF(TTM)10.53
FCFY6.31%
OCF(TTM)14.98
OCFY8.97%
SpS81.56
BVpS64.28
TBVpS1.23
PEG (NY)1.92
PEG (5Y)3.4
Graham Number121.94
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.02% | ||
| ROE | -4.56% | ||
| ROCE | 8.35% | ||
| ROIC | 6.6% | ||
| ROICexc | 6.84% | ||
| ROICexgc | 14.71% | ||
| OM | 12.51% | ||
| PM (TTM) | N/A | ||
| GM | 34.98% | ||
| FCFM | 12.91% |
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
ROICexc(3y)7.1%
ROICexc(5y)7.66%
ROICexgc(3y)16.12%
ROICexgc(5y)18.95%
ROCE(3y)8.67%
ROCE(5y)9.34%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-5.63%
ROICexc growth 3Y-6.27%
ROICexc growth 5Y-3.36%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | 4.13 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 54.34% | ||
| Cap/Sales | 5.46% | ||
| Interest Coverage | 4.94 | ||
| Cash Conversion | 81.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | 2.42 |
F-Score5
WACC10.52%
ROIC/WACC0.63
Cap/Depr(3y)73.38%
Cap/Depr(5y)82.63%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
EPS Next Y8.47%
EPS Next 2Y8.74%
EPS Next 3Y8.89%
EPS Next 5Y9.31%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
Revenue Next Year-0.59%
Revenue Next 2Y1.18%
Revenue Next 3Y2.21%
Revenue Next 5Y3.54%
EBIT growth 1Y-8.84%
EBIT growth 3Y-8.7%
EBIT growth 5Y2.04%
EBIT Next Year25.47%
EBIT Next 3Y11.29%
EBIT Next 5Y9.93%
FCF growth 1Y3.37%
FCF growth 3Y20.69%
FCF growth 5Y6.41%
OCF growth 1Y0.42%
OCF growth 3Y5.98%
OCF growth 5Y6.18%
CHARLES RIVER LABORATORIES / CRL Fundamental Analysis FAQ
What is the fundamental rating for CRL stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRL.
What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?
ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.
Can you provide the profitability details for CHARLES RIVER LABORATORIES?
CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.
What is the valuation of CHARLES RIVER LABORATORIES based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CHARLES RIVER LABORATORIES (CRL) is 16.25 and the Price/Book (PB) ratio is 2.6.
What is the financial health of CHARLES RIVER LABORATORIES (CRL) stock?
The financial health rating of CHARLES RIVER LABORATORIES (CRL) is 4 / 10.